Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Esteve Pharmaceuticals synthesizes new dual CACNA2D1/NET ligands

May 13, 2019

LY-3154207 demonstrates linear plasma PK and promising safety in healthy volunteers

May 13, 2019

Impaired placental function linked to neurodevelopmental disorders

May 13, 2019

First clinical results on K-0706 presented as potential treatment for Parkinson's disease

May 10, 2019

First patient dosed in phase II trial of SRK-015 in type 2 and type 3 SMA

May 9, 2019

Phase I results presented for LY-3154207

May 9, 2019

Neuropore initiates phase I study of NPT-520-34

May 9, 2019

NEOLEV2 trial highlights the difficulty of treating neonatal seizures

May 9, 2019

Merck & Co. patents LRKK2-mutant inhibitors

May 8, 2019

Pilot study of L1-79 demonstrates trends towards improvement in male subjects with ASD

May 8, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.